trans-3-(naphth-2-yl)-but-2-enoic acid chloride

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: trans-3-(naphth-2-yl)-but-2-enoic acid chloride
• 英文别名: (Z)-3-naphthalen-2-ylbut-2-enoyl chloride
• 化学式: C₁₄H₁₁ClO
• 分子量: 230.694
• InChiKey: DBZSKMGYRKKNEZ-NTMALXAHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  trans-3-(naphth-2-yl)-but-2-enoic acid chloride 在 吡啶 、 lithium hydroxide 作用下， 以 四氢呋喃 、 乙醚 为溶剂， 反应 17.0h， 生成 trans-3-(naphth-2-yl)-but-2-enoic acid-N-(2-carboxy-phenyl)-amide
  参考文献：
  名称：

  Inhibition of telomerase by BIBR 1532 and related analogues

  摘要：

  BIBR 1532 has been reported to be a potent, small molecule inhibitor of human telomerase, suggesting it as a lead for the development of anti-telomerase therapy. We confirm the ability of BIBR 1532 to inhibit telomerase and report the discovery of an equally potent analogue. Importantly, IC50 values in cell extract are considerably higher than those previously reported using assays for purified enzyme, indicating that substantial improvement may be necessary. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00101-x
• 作为产物：
  描述：

  methyl (Z)-3-(naphthalen-2-yl)-but-2-enoate 在 lithium hydroxide 、 氯化亚砜 、 N,N-二甲基甲酰胺 作用下， 以 四氢呋喃 为溶剂， 反应 14.0h， 生成 trans-3-(naphth-2-yl)-but-2-enoic acid chloride
  参考文献：
  名称：

  Inhibition of telomerase by BIBR 1532 and related analogues

  摘要：

  BIBR 1532 has been reported to be a potent, small molecule inhibitor of human telomerase, suggesting it as a lead for the development of anti-telomerase therapy. We confirm the ability of BIBR 1532 to inhibit telomerase and report the discovery of an equally potent analogue. Importantly, IC50 values in cell extract are considerably higher than those previously reported using assays for purified enzyme, indicating that substantial improvement may be necessary. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00101-x

文献信息

• Carboxylic acid amides, pharmaceutical compositions containing these compounds and their use
  申请人：Boehringer Ingelheim Pharma KG

  公开号：US06362210B1

  公开（公告）日：2002-03-26

  Carboxylic acid amides of general formula which inhibit telomerase and are useful for treating tumour diseases such as carcinomas, sarcomas and leukaemias. Exemplary compounds are: (1) trans-3-(naphth-2-yl)-but-2-enoic acid-N-(2-carboxy-phenyl)-amide, and, (2) trans-3-(naphth-2-yl)-but-2-enoic acid-N-(2-carboxy-4,5-dimethoxy-phenyl)-amide.

  通用公式为的羧酸酰胺，抑制端粒酶，可用于治疗癌症、肉瘤和白血病等肿瘤疾病。示例化合物包括： (1) 反-3-(萘-2-基)-丁-2-烯酸-N-(2-羧基苯基)-酰胺，以及， (2) 反-3-(萘-2-基)-丁-2-烯酸-N-(2-羧基-4,5-二甲氧基苯基)-酰胺。
• Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and the preparation thereof
  申请人：——

  公开号：US20020128495A1

  公开（公告）日：2002-09-12

  The present application relates to carboxylic acid amides of general formula 1 wherein A, B and R 1 to R 3 are defined as in claim 1, processes for preparing them, pharmaceutical compositions containing these compounds and the use thereof and their preparation.

  本申请涉及通式1的羧酸酰胺，其中A、B和R1至R3如权利要求1中所定义，制备它们的工艺，含有这些化合物的制药组合物及其用途和制备方法。
• Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation
  申请人：——

  公开号：US20020099089A1

  公开（公告）日：2002-07-25

  Carboxylic acid amides of general formula 1 which inhibit telomerase and are useful for treating tumor diseases such as carcinomas, sarcomas and leukaemias. Exemplary compounds are: (1) trans-3-(naphth-2-yl)-but-2-enoic acid-N-(2-carboxy-phenyl)-amide, and, (2) trans-3-(naphth-2-yl)-but-2-enoic acid-N-(2-carboxy-4,5-dimethoxy-phenyl)-amide.

  通式为1的羧酸酰胺具有抑制端粒酶的作用，可用于治疗肿瘤疾病，如癌症、肉瘤和白血病。其中示例化合物为：(1) 反-3-(萘-2-基)-丁-2-烯酸-N-(2-羧基苯基)-酰胺，和，(2) 反-3-(萘-2-基)-丁-2-烯酸-N-(2-羧基-4,5-二甲氧基苯基)-酰胺。
• CARBONSÄUREAMIDE, DIESE VERBINDUNGEN ENTHALTENDE ARZNEIMITTEL, DEREN VERWENDUNG UND HERSTELLUNG
  申请人：Boehringer Ingelheim Pharma KG

  公开号：EP1261321A2

  公开（公告）日：2002-12-04
• US6362210B1
  申请人：——

  公开号：US6362210B1

  公开（公告）日：2002-03-26